8-K: Processa Pharmaceuticals Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Compliance

Processa Pharmaceuticals will implement a 1-for-20 reverse stock split effective January 22, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Summary

• Processa Pharmaceuticals has announced a 1-for-20 reverse stock split of its common stock.
• The reverse stock split will be effective on January 22, 2024, at 12:01 a.m. Eastern Time.
• Every twenty shares of existing common stock will be converted into one share of new common stock.
• The company will not issue fractional shares; instead, fractional shares will be rounded up to the nearest whole share.
• The reverse stock split aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• The number of outstanding shares will decrease from approximately 24.6 million to approximately 1.2 million.
• The reverse stock split will not change the par value of the common stock or the ownership percentage of stockholders, except for the impact of fractional shares.
• Adjustments will be made to outstanding equity awards, warrants, and shares issuable under equity incentive plans.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the need for a reverse stock split to maintain Nasdaq listing, indicating underlying issues with the company's share price performance. While the company is taking action to address the issue, the situation is not ideal.

Positives

• The reverse stock split is a strategic move to ensure continued listing on the Nasdaq Capital Market.
• The company will not issue fractional shares, simplifying the process for shareholders.
• The ownership percentage of each stockholder will remain unchanged, except for the impact of fractional shares.

Negatives

• The reverse stock split is a result of the company's share price falling below the Nasdaq minimum bid price requirement.
• The number of outstanding shares will be significantly reduced, which may impact trading volume.

Risks

• The reverse stock split may not be sufficient to maintain compliance with Nasdaq listing requirements if the share price does not increase.
• There is a risk that the reverse stock split could negatively impact investor sentiment.

Future Outlook

The company intends to maintain its Nasdaq listing through the reverse stock split and continue its drug development programs.

Management Comments

• The company's Board of Directors determined to fix a split ratio of 1-for-20.
• The reverse stock split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on the Nasdaq Capital Market.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low share prices. This action is often seen in the biotechnology and pharmaceutical sectors where companies may experience volatility in their stock price due to the nature of drug development and regulatory approvals.

Comparison to Industry Standards

• Many small-cap biotech companies have used reverse stock splits to maintain exchange listings, such as Agenus Inc. (AGEN) which implemented a 1-for-10 reverse split in 2023 and BioDelivery Sciences International (BDSI) which implemented a 1-for-10 reverse split in 2021.
• The 1-for-20 ratio is relatively high compared to some other reverse stock splits, which often range from 1-for-2 to 1-for-10, indicating a significant drop in the share price.
• The need for a reverse stock split suggests that Processa's share price has been underperforming compared to industry benchmarks, which is not uncommon for companies in the clinical stage of drug development.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their ownership percentage will remain the same, except for the impact of fractional shares.
• The reverse stock split is intended to maintain the company's listing on the Nasdaq, which is important for investor confidence.

Next Steps

• The company's common stock will begin trading on a reverse stock split-adjusted basis on January 22, 2024.
• Registered stockholders holding shares electronically will have their shares automatically adjusted.
• Stockholders holding shares in certificate form will receive a transmittal letter with instructions from Continental Stock Transfer & Trust.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, minimum bid price, common stock, shareholder, PCSA, Processa Pharmaceuticals